Mahadev Drugs Gujarat Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 12-07-2024
- Paid Up Capital ₹ 6.24 M
as on 12-07-2024
- Company Age 28 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 105.91%
(FY 2016)
- Profit 447.19%
(FY 2016)
- Ebitda 72.97%
(FY 2016)
- Net Worth 1.24%
(FY 2016)
- Total Assets 1.24%
(FY 2016)
About Mahadev Drugs Gujarat
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 6.24 M, as per Ministry of Corporate Affairs (MCA) records.
Vitthal Rungta, Sanjaykumar Rungta, and Sunita Rungta serve as directors at the Company.
- CIN/LLPIN
U24231GJ1996PTC028927
- Company No.
028927
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Feb 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mahadev Drugs Gujarat?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vitthal Rungta  | Director | 20-Mar-2015 | Current |
| Sanjaykumar Rungta | Director | 27-Feb-1996 | Current |
| Sunita Rungta | Director | 20-Mar-2015 | Current |
Financial Performance of Mahadev Drugs Gujarat.
Mahadev Drugs Gujarat Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 105.91% increase. The company also saw a substantial improvement in profitability, with a 447.19% increase in profit. The company's net worth moved up by a moderate rise of 1.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mahadev Drugs Gujarat?
In 2017, Mahadev Drugs Gujarat had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Shiromani Infrastructure LimitedActive 29 years 2 months
Vitthal Rungta and Sunita Rungta are mutual person
- Triohix FoundationActive 2 years 11 months
Vitthal Rungta, Sanjaykumar Rungta and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mahadev Drugs Gujarat?
Unlock and access historical data on people associated with Mahadev Drugs Gujarat, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mahadev Drugs Gujarat, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mahadev Drugs Gujarat's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
